These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 10196026)

  • 1. Meropenem pharmacokinetics in a patient with multiorgan failure from Meningococcemia undergoing continuous venovenous hemodiafiltration.
    Meyer MM; Munar MY; Kohlhepp SJ; Bryant RE
    Am J Kidney Dis; 1999 Apr; 33(4):790-5. PubMed ID: 10196026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of meropenem in intensive care unit patients receiving continuous veno-venous hemofiltration or hemodiafiltration.
    Giles LJ; Jennings AC; Thomson AH; Creed G; Beale RJ; McLuckie A
    Crit Care Med; 2000 Mar; 28(3):632-7. PubMed ID: 10752806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elimination of meropenem during continuous veno-venous haemofiltration and haemodiafiltration in patients with acute renal failure.
    Valtonen M; Tiula E; Backman JT; Neuvonen PJ
    J Antimicrob Chemother; 2000 May; 45(5):701-4. PubMed ID: 10797097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and dosage adaptation of meropenem during continuous venovenous hemodiafiltration in critically ill patients.
    Robatel C; Decosterd LA; Biollaz J; Eckert P; Schaller MD; Buclin T
    J Clin Pharmacol; 2003 Dec; 43(12):1329-40. PubMed ID: 14615469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are interstitial fluid concentrations of meropenem equivalent to plasma concentrations in critically ill patients receiving continuous renal replacement therapy?
    Varghese JM; Jarrett P; Wallis SC; Boots RJ; Kirkpatrick CM; Lipman J; Roberts JA
    J Antimicrob Chemother; 2015 Feb; 70(2):528-33. PubMed ID: 25336163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of meropenem in patients with renal failure and patients receiving renal replacement therapy.
    Thalhammer F; Hörl WH
    Clin Pharmacokinet; 2000 Oct; 39(4):271-9. PubMed ID: 11069213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of continuous venovenous hemofiltration and continuous venovenous hemodiafiltration on the disposition of doripenem.
    Cirillo I; Vaccaro N; Balis D; Redman R; Matzke GR
    Antimicrob Agents Chemother; 2011 Mar; 55(3):1187-93. PubMed ID: 21199922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of meropenem in critically ill patients with acute renal failure undergoing continuous venovenous hemofiltration.
    Tegeder I; Neumann F; Bremer F; Brune K; Lötsch J; Geisslinger G
    Clin Pharmacol Ther; 1999 Jan; 65(1):50-7. PubMed ID: 9951430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Doripenem population pharmacokinetics and dosing requirements for critically ill patients receiving continuous venovenous haemodiafiltration.
    Roberts JA; Udy AA; Bulitta JB; Stuart J; Jarrett P; Starr T; Lassig-Smith M; Roberts NA; Dunlop R; Hayashi Y; Wallis SC; Lipman J
    J Antimicrob Chemother; 2014 Sep; 69(9):2508-16. PubMed ID: 24879665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of meropenem in plasma and filtrate-dialysate from patients under continuous veno-venous haemodiafiltration by SPE-LC.
    Robatel C; Buclin T; Eckert P; Schaller MD; Biollaz J; Decosterd LA
    J Pharm Biomed Anal; 2002 Jun; 29(1-2):17-33. PubMed ID: 12062661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-dose pharmacokinetics of meropenem during continuous venovenous hemofiltration.
    Thalhammer F; Schenk P; Burgmann H; El Menyawi I; Hollenstein UM; Rosenkranz AR; Sunder-Plassmann G; Breyer S; Ratheiser K
    Antimicrob Agents Chemother; 1998 Sep; 42(9):2417-20. PubMed ID: 9736573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of meropenem in critically ill patients with acute renal failure treated by continuous hemodiafiltration.
    Krueger WA; Schroeder TH; Hutchison M; Hoffmann E; Dieterich HJ; Heininger A; Erley C; Wehrle A; Unertl K
    Antimicrob Agents Chemother; 1998 Sep; 42(9):2421-4. PubMed ID: 9736574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Individual Meropenem Clearance in Infants on ECMO and CVVHDF is Difficult to Predict: A Case Report and Review of the Literature.
    Jabareen A; Nassar L; Karasik M; Efrati E; Hadash A; Kassis I; Kurnik D
    Pediatr Infect Dis J; 2022 Feb; 41(2):117-120. PubMed ID: 34966143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and dosing regimen of meropenem in critically ill patients receiving continuous venovenous hemofiltration.
    Ververs TF; van Dijk A; Vinks SA; Blankestijn PJ; Savelkoul JF; Meulenbelt J; Boereboom FT
    Crit Care Med; 2000 Oct; 28(10):3412-6. PubMed ID: 11057794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuous infusion of ceftazidime in critically ill patients undergoing continuous venovenous haemodiafiltration: pharmacokinetic evaluation and dose recommendation.
    Mariat C; Venet C; Jehl F; Mwewa S; Lazarevic V; Diconne E; Fonsale N; Carricajo A; Guyomarc'h S; Vermesch R; Aubert G; Bidault R; Bertrand JC; Zeni F
    Crit Care; 2006 Feb; 10(1):R26. PubMed ID: 16507147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of moxifloxacin in patients undergoing continuous venovenous haemodiafiltration.
    Fuhrmann V; Schenk P; Jaeger W; Ahmed S; Thalhammer F
    J Antimicrob Chemother; 2004 Oct; 54(4):780-4. PubMed ID: 15347636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meropenem and continuous renal replacement therapy: in vitro permeability of 2 continuous renal replacement therapy membranes and influence of patient renal function on the pharmacokinetics in critically ill patients.
    Isla A; Maynar J; Sánchez-Izquierdo JA; Gascón AR; Arzuaga A; Corral E; Pedraz JL
    J Clin Pharmacol; 2005 Nov; 45(11):1294-304. PubMed ID: 16239363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic modeling and dosage adaptation of biapenem in Japanese patients during continuous venovenous hemodiafiltration.
    Ikawa K; Morikawa N; Ikeda K; Suyama H
    J Infect Chemother; 2008 Feb; 14(1):35-9. PubMed ID: 18297447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An evaluation of ciprofloxacin pharmacokinetics in critically ill patients undergoing continuous veno-venous haemodiafiltration.
    Spooner AM; Deegan C; D'Arcy DM; Gowing CM; Donnelly MB; Corrigan OI
    BMC Clin Pharmacol; 2011 Aug; 11():11. PubMed ID: 21816053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elimination of meropenem by continuous hemo(dia) filtration: an in vitro one-compartment model.
    Schroeder TH; Krueger WA; Hansen M; Hoffmann E; Dieterich HJ; Unertl K
    Int J Artif Organs; 1999 May; 22(5):307-12. PubMed ID: 10467928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.